The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Approaching the treatment of lenalidomide refractory patients with multiple myeloma
At present, lenalidomide refractory patients with multiple myeloma (MM) present a significant clinical unmet need, with poor outcomes seen outside of clinical trials. In this video, Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, emphasizes the potential of novel treatments, such as bispecific antibody-based regimens and agents like mezigdomide, which may improve patient outcomes and quality of life. Dr Cerchione also highlights the need for updated treatment guidelines to reflect these advancements as they occur. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
